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ABSTRACT
Objective: Serine palmitoyltransferase (SPT) catalyzes
the condensation of serine and palmitoyl coenzyme A,
the first step in the de novo sphingolipid synthesis.
Apart from these canonical substrates, SPT can also
metabolize alanine and other acyl coenzyme As. This
forms a spectrum of atypical sphingoid bases which
are altered in the context of the metabolic syndrome
(MetS) and type 2 diabetes mellitus (T2DM). We
investigated whether atypical sphingolipids can be used
as prospective markers to predict the incidence of
T2DM.
Research design and methods: Using liquid
chromatography/mass spectrometry, we analyzed the
sphingoid base profile in a prospective cohort with 339
individuals. All individuals were followed up for a
period of 8 years.
Results: Confirming earlier results, we found
1-deoxysphingolipids (1-deoxySLs) to be significantly
elevated in patients with MetS, impaired fasting
glucose, and T2DM. Patients who developed T2DM
during the follow-up period (n=32) showed
significantly higher 1-deoxySL levels at baseline
compared with those who did not develop T2DM until
the end of the study (n=70). 1-Deoxysphingosine levels
were independent predictors for T2DM even after
adjusting for glycated hemoglobin (standardized
adjusted OR=2.1, CI 95% (1.19 to 3.71); p=0.010),
MetS (standardized adjusted OR=1.97, CI 95% (1.13 to
3.43); p=0.017), and other risk factors such as age,
sex, BMI, and lipid-lowering drugs. Similar results were
observed for the 1-deoxysphinganine levels.
Conclusions: Our results support a novel role for
1-deoxySL as predictive biomarkers for the
development of T2DM in risk patients and warrants
further larger prospective trials in lower risk cohorts.
INTRODUCTION
Diabetes mellitus type 2 (T2DM) remains a
major cause of mortality and morbidity
worldwide, despite the advances in risk pre-
diction, diagnosis, and management.
Traditional risk factors such as impaired
fasting glucose (IFG) and impaired glucose
tolerance fail to predict almost 50% of the
patients who will develop T2DM.1 2 This fact
has fueled an expanding research pursuit to
identify risk factors and novel biomarkers to
improve risk prediction.3 4 With the progress
in mass spectrometry and nuclear magnetic
resonance spectroscopy, many blind spots in
the human plasma metabolome and lipi-
dome are becoming visible and quantiﬁable.
In fact, several metabolites such as acylcarni-
tines, amino acids, phospholipids, and also
sphingolipids have become candidates of bio-
markers for the prediction of future
T2DM.5–7
Sphingolipids comprise a heterogeneous
class of lipids including free sphingoid bases,
ceramides, sphingomyelins, and glycosphin-
golipids. Sphingoid bases are the shared
structural element in all sphingolipids and
typically formed by the condensation of
L-serine and palmitoyl coenzyme A. This
reaction is catalyzed by the enzyme serine
palmitoyltransferase (SPT)8–10 forming
C18-sphinganine (C18SA), which is then sub-
sequently N-acylated to (dihydro)-ceramides.
Ceramides are bioactive lipids which serve as
building blocks for the synthesis of complex
sphingolipids like sphingomyelins or
gylcosphingolipids.
There is increasing evidence that sphingoli-
pids are actively involved in the development
of T2DM.11 Ceramides were shown to
Key messages
▪ 1-Deoxysphingolipids (1-deoxySLs) are signifi-
cantly elevated in patients with impaired fasting
glucose, metabolic syndrome (MetS), and T2DM.
▪ 1-DeoxySLs are independent predictors for the
risk to develop T2DM even after adjusting for
glycated hemoglobin and the presence of MetS.
▪ Although plasma triglycerides and 1-deoxySLs
showed a high collinearity, stepwise logistic
regression analysis revealed 1-deoxySLs as inde-
pendent predictors for T2DM.
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counteract the insulin action on glucose uptake and glyco-
gen synthesis by inhibiting protein kinase B/Akt through
different mechanisms,12 and it was demonstrated recently
that many of the beneﬁcial effects of adiponectin on β-cell
survival in T2DM are linked to its lowering effect on intra-
cellular ceramide levels.13 Moreover, plasma levels of cera-
mides were found to be elevated in patients with T2DM14
and to correlate with the degree of insulin resistance in
these patients. In contrast, sphingomyelin and gylcosphin-
golipids were found to be decreased in plasma of diabetic
monkeys.15 Myriocin, a potent SPT inhibitor, was shown to
improve insulin resistance and preclude the development
of T2DM in animal models.16 Apart from the canonical
substrates, SPT is also able to metabolize other acyl coen-
zyme As in the range of C12 to C18, which results in a spec-
trum of sphingoid bases with variable carbon chain
length. Under certain conditions, SPT can also use other
amino acids such as L-alanine and partly also glycine as
alternative substrates.17 This generates an atypical class of
neurotoxic 1-deoxysphingolipids (1-deoxySL) which lack
the C1 hydroxyl group of canonical sphingolipids. SPT is
positioned at a metabolic cross-point which metabolically
interconnects fatty acid, amino acid (serine, alanine, and
glycine), and thereby indirectly also the carbohydrate
metabolism.
We showed previously that 1-deoxyspingolipids
(1-deoxySLs) are signiﬁcantly elevated in the plasma of
individuals with metabolic syndrome (MetS)18 and
T2DM.19 In this follow-up study, we aimed to investigate
the ability of 1-deoxySLs to predict incident diabetes by
analyzing the sphingoid base proﬁle in a prospective
cohort with 339 individuals.
RESEARCH DESIGN AND METHODS
Patients and study design
For this study, a group of 339 patients were selected
from a prospective cohort study of patients who under-
went coronary angiography for the evaluation of estab-
lished or suspected stable coronary artery disease
(CAD).20 The group was selected based on the availabil-
ity of baseline and follow-up data for T2DM. The study
participants were enrolled into the study between
September 1999 and October 2000. Anthropometric
data were collected, clinical chemistry laboratory para-
meters were measured, and coronary angiography
( Judkin’s technique) was performed on all study partici-
pants at baseline. Coronary artery stenoses with lumen
narrowing of 50% or more were considered signiﬁcant,
and coronary arteries were deﬁned as normal in the
absence of any visible lumen narrowing at angiography.
All participants gave written informed consent.
Diagnosis
Diabetes at baseline was diagnosed according to the
WHO criteria, that is, fasting glucose levels ≥7 mmol/L
(126 mg/dL), plasma glucose levels ≥11.1 mmol/L
(200 mg/dL) 2 h after an oral glucose challenge (75 g),
or a previous physician diagnosis of T2DM.
Metabolic syndrome at baseline was deﬁned according
to the criteria of the National Cholesterol Education
Program-Adult Treatment Panel III criteria, if three or
more of the following criteria were met: waist circumfer-
ence >102 cm in men or >88 cm in women; triglycerides
(TGs) ≥1.7 mmol/L (150 mg/dL); high-density lipopro-
tein (HDL) cholesterol <1.0 mmol/L (40 mg/dL) in
men or <1.3 mmol/L (50 mg/dL) in women; blood
pressure ≥130/≥85 mm Hg; and fasting glucose
≥6.1 mmol/L (110 mg/dL). Patients with fasting
glucose ≥7 mmol/L (126 mg/dL) at baseline were diag-
nosed with T2DM, patients with fasting glucose between
5.6 and 6.9 mmol/L (100–125 mg/dL) were diagnosed
as IFG while those with fasting glucose <5.6 mmol/L
were diagnosed as normal fasting glucose (NFG).
Prospective study
For the diagnosis of incident T2DM, blood samples were
collected 2, 4, 6 and 8 years after enrollment. Individuals
were considered to have incident diabetes if one of the
three criteria was met at any of the follow-up examina-
tions: fasting glucose levels ≥7 mmol/L (126 mg/dL),
plasma glucose levels ≥11.1 mmol/L (200 mg/dL) 2 h
after an oral glucose challenge (75 g), or the clinical
diagnosis of T2DM by a physician during the follow-up
period. Individuals were classiﬁed to be free from inci-
dent T2DM if both conditions were met; fasting glucose
levels <7 mmol/L (126 mg/dL) and plasma glucose
levels <11.1 mmol/L (200 mg/dL) 2 h after an oral chal-
lenge with 75 g glucose at all follow-up visits. Individuals
with missing values for fasting plasma glucose or 2 h
post-glucose challenge were excluded. From the total
cohort, 105 participants fulﬁlled either the criteria of
incident T2DM (n=32) or the absence of incident
T2DM (n=70) and were included in the prospective
analysis.
Clinical chemistry
Venous blood samples were collected after overnight
fasting and at least 12 h before angiography. Laboratory
analysis was performed on fresh serum or blood
samples. Glycated hemoglobin (HbA1c) was analyzed
by high-performance liquid chromatography on a
Menarini-Arkray KDK HA 8140 (Arkray KDK, Kyoto,
Japan). Triacylglycerols, total cholesterol, HDL, and
other clinical chemistry variables were measured on a
Hitachi 717 or 911 system (Roche).
Sphingolipid analysis
The sphingoid base proﬁle was analyzed as described
before18 with some modiﬁcations. Brieﬂy, 0.5 mL metha-
nol including 200 pmol of the internal standards
d7-sphingosine and d7-sphinganine (d7SA, d7SO; Avanti
Polar Lipids, Alabaster, Alabama, USA) was added to
100 µL of plasma and extracted for 1 h under agitation
on a thermomixer at 37°C. Precipitated proteins were
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pelleted by centrifugation and the supernatant trans-
ferred to a new tube. For lipid hydrolysis, 75 μL of
methanolic HCl (1 N HCl and 10 M H2O in methanol)
was added to the supernatant and incubated for 16 h at
65°C. This was followed by the addition of 100 μL of
10 M KOH to neutralize the HCl and hydrolyze the
phospholipids. To this mix, 625 µL chloroform was
added. Then, 100 µL 2N ammonium hydroxide and
0.5 mL alkaline water were added to complete the phase
separation. The mix was then vortexed and centrifuged
at 16 000g for 5 min. After centrifugation, the upper
phase was discarded and the lower organic phase was
washed 2–3 times with alkaline water (pH 10.3). Finally,
the organic phase was dried under N2 and kept at −20°
C until analysis.
The sphingoid bases were separated on a C18 column
(Uptispere 120 Å, 5 µm, 125×2 mm, Interchim, Montluçon,
France) and analyzed on a TSQ Quantum Ultra mass
spectrometer (Thermo, Reinach, BL, Switzerland). Each
sample was measured as a singleton. Intra assay and
inter assay coefﬁcient of variation (%) of the method
was between 5% and 20%.
Table 1 Baseline characteristics of patients with MetS and individuals free of MetS
No MetS at baseline (n=192) MetS at baseline (n=147) p Value
Age (years) 64.2±10.1 61.2±9.7 0.006
Sex (female) 65 (33.85%) 43 (29.25%) 0.367
Hypertension (WHO) 78 (40.63%) 98 (66.67%) 1.98E-06
T2DM (baseline) 31 (16.15%) 77 (52.38%) 1.28E-12
History of smoking 106 (55.21%) 97 (65.99%) 0.045
Coronary artery stenosis >50% 112 (58.33%) 98 (66.67%) 0.117
BMI 26±4.1 28.9±4.2 4.59E-11
Waist circumference (cm) 91.6±10.7 101.6±11.4 3.92E-14
Waist-to-hip ratio 0.9±0.1 1.0±0.1 2.91E-08
Cholesterol (mmol/L) 5.6±1 5.6±1.2 0.478
LDL (mmol/L) 3.4±0.8 3.3±0.9 0.068
HDL (mmol/L) 1.4±0.4 1±0.3 4.49E-19
Triglycerides (mmol/L) 1.4±0.5 2.5±1.6 3.18E-22
Glucose (mmol/L) 6±1.8 7.7±2.5 9.56E-20
HbA1c (%) 6±0.8 6.7±1.4 2.06E-07
Insulin (µU/mL) 9.1±7.6 16.7±15.5 2.98E-13
HOMA-IR 2.4±2.2 5.5±4.5 2.0E-18
Systolic BP 130.8±21.1 145±21 4.82E-10
Diastolic BP 76.3±12.3 82.2±12.2 8.29E-06
CRP 0.7±1 1.1±1.7 2.65E-05
Serum potassium 4.4±0.4 4.4±0.5 0.656
Creatinine (mg/dL) 1.1±0.5 1.2±0.7 0.053
GFR (Mayo) 86.6±18.6 85±21.4 0.973
T2DM treatment 31 (16.15%) 77 (52.38%) 1.28E-12
Diuretics 58 (30.21%) 60 (40.82%) 0.042
Antihypertensive drugs 149 (77.6%) 127 (86.39%) 0.039
Lipid-lowering drugs 90 (46.88%) 79 (53.74%) 0.210
Plasma sphingolipids
C16SO (µmol/L) 15.32±5.38 14.19±5.4 0.022
C16SA (µmol/L) 0.45±0.19 0.5±0.29 0.220
C17SO (µmol/L) 8.13±2.73 7.22±2.45 0.002
C18PhytoSO (µmol/L) 0.12±0.04 0.11±0.05 0.066
C18SAdiene (µmol/L) 28.22±7.71 26.22±7.88 0.014
C18SO (µmol/L) 94.77±18.48 89.79±22.77 0.019
C18SA (µmol/L) 3.21±1.04 3.66±1.84 0.065
C19SO (µmol/L) 2.88±1.2 2.65±1.19 0.043
C20SO (µmol/L) 0.17±0.05 0.18±0.06 0.039
C20SA (µmol/L) 0.02±0.01 0.03±0.01 2.81E-04
1-deoxySO (µmol/L) 0.15±0.09 0.21±0.14 5.65E-06
1-deoxySA (µmol/L) 0.07±0.03 0.09±0.06 3.26E-05
Values are shown as mean±SD for the continuous variables and numbers and per cent of total for the categorical variables. p Values were
calculated using the unpaired two-sided t test on the log-transformed continuous variables. For the categorical variables, the p value was
calculated using the χ2 test. Variables in bold font have significant differences after the Bonferroni correction (p<0.001).
BMI, body mass index; CRP, C reaction protein; GFR (Mayo), Glomerular filtration rate (Mayo equation); Hb, hemoglobin; HbA1c, glycated
Hb; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; LDL, low-density lipoprotein; MetS, metabolic
syndrome; SA, sphinganine; SO, sphingosine; T2DM, type 2 diabetes mellitus.
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Sphingoid bases in plasma are typically N-acylated and
conjugated to different headgroups.21 It is important to
note that 1-deoxySLs lack the C1 hydroxyl group of typical
SLs and therefore cannot form complex sphingolipids
such as sphingomyelin or glycosphingolipids. Plasma
1-deoxySLs can be present as 1-deoxysphinganine
(1-deoxySA) or 1-deoxysphingosine (1-deoxySO)) and in
the N-acylated forms (1-deoxy-dihydro-ceramides and 1-
deoxyceramides, respectively).22 We performed an acid/base
hydrolysis prior to analysis and quantiﬁed the total amount
of all long-chain bases (which reﬂects the SPT activity). At
that stage, we cannot distinguish between the free base and
N-acyls anymore. Therefore, the reported sphingoid base
concentrations do not reﬂect the original levels of free
Table 2 Baseline characteristics of patients with NFG, IFG, and T2DM
NFG at baseline
(n=124)
IFG at baseline
(n=107)
T2DM at baseline
(n=108) p Value
Age (years) 62.5±10.3 63.6±10.1 62.7±9.7 0.708
Sex (female) 48 (38.71%) 27 (25.23%) 33 (30.56%) 0.085
Hypertension (WHO) 56 (45.16%) 64 (59.81%) 56 (51.85%) 0.085
History of smoking 70 (56.45%) 61 (57.01%) 72 (66.67%) 0.218
Coronary artery stenosis >50% 71 (57.26%) 65 (60.75%) 74 (68.52%) 0.202
MetS ATP III Definition 26(20.97%) 44 (41.12%)* 77 (71.3%)*§ 1.01E-13
BMI 26.4±4.6 27.3±4 28.2±4.3 0.006
Waist circumference (cm) 91.9±12 97±10.7 99.4±12.2* 9.54E-06
Waist-to-hip ratio 0.9±0.1 1±0.1 1±0.1* 1.60E-04
Cholesterol (mmol/L) 5.6±1.1 5.7±1 5.4±1.2 0.133
LDL (mmol/L) 3.4±0.8 3.5±0.8 3.1±0.9 0.001
HDL (mmol/L) 1.3±0.4 1.3±0.4 1.1±0.4 0.001
Triglycerides (mmol/L) 1.7±1.1 1.7±0.8 2.3±1.7* 3.39E-05
Glucose (mmol/L) 5.3±0.9 6.2±0.5* 8.9±2.8*§ 7.81E-55
HbA1c (%) 5.8±0.5 5.9±0.5 7.5±1.4* 4.44E-44
Insulin (µU/mL) 9.4±13.5 12.9±10.5* 15.4±11.8*§ 2.39E-08
HOMA-IR 1.9±1.2 3.6±3.1* 5.9±4.9*§ 3.64E-23
Systolic BP 133.3±22.7 138.7±21.3 139.6±22 0.040
Diastolic BP 77.9±12.6 79.7±11.2 79.2±13.9 0.457
CRP 0.7±1.1 0.9±1.7 1±1.2 0.058
Serum potassium 4.4±0.4 4.3±0.4 4.5±0.5 0.070
Creatinine (mg/dL) 1.2±0.9 1.1±0.2 1.2±0.4 0.640
GFR (Mayo) 86.2±19.7 86.8±17.3 84.7±22.4 0.496
Diuretics 33 (26.61%) 35 (32.71%) 50 (46.3%) 0.006
Antihypertensive drugs 93 (75%) 87 (81.31%) 96 (88.89%) 0.025
Lipid-lowering drugs 58 (46.77%) 49 (45.79%) 62 (57.41%) 0.162
Plasma sphingolipids
C16SO (µmol/L) 15.26±6.46 14.67±4.38 14.5±5.03 0.695
C16SA (µmol/L) 0.44±0.26 0.48±0.21 0.49±0.23 0.096
C17SO (µmol/L) 8.11±3 7.74±2.43 7.31±2.38 0.165
C18PhytoSO (µmol/L) 0.12±0.05 0.11±0.04 0.11±0.04 0.792
C18SAdiene (µmol/L) 28.64±8.57 27.21±6.86 26.01±7.68 0.033
C18SO (µmol/L) 94.56±22.14 92.67±19.29 90.3±19.85 0.250
C18SA (µmol/L) 3.16±1.44 3.38±1.15 3.7±1.69 0.027
C19SO (µmol/L) 2.88±1.33 2.82±1.15 2.62±1.08 0.262
C20SO (µmol/L) 0.17±0.06 0.18±0.05 0.18±0.05 0.028
C20SA (µmol/L) 0.02±0.01 0.03±0.01 0.03±0.02* 1.33E-05
1-deoxySO (µmol/L) 0.14±0.1 0.17±0.09 0.22±0.14* 2.22E-06
1-deoxySA (µmol/L) 0.07±0.05 0.08±0.03 0.09±0.05 0.001
Values are shown as mean ±SD for the continuous variables and numbers and percentage of total for the categorical variables. p Values
were calculated using the ANOVA followed by the Bonferroni correction on the log transformed continuous variables. For the categorical
variables, the p value was calculated using the χ2 test. Variables in bold font have significant differences after the Bonferroni correction
(p=4.1×10−4). The three groups were compared with each other.
*Represent a significant difference from NFG.
§Represents a significant difference from IFG.
ANOVA, analysis of variance; ATP, Adult Treatment Panel; BMI, body mass index; CRP, C reaction protein; GFR (Mayo) Glomerular filtration
rate (Mayo equation); Hb, hemoglobin; HbA1c, glycated Hb; HDL, high-density lipoprotein; HOMA-IR, Homeostatic model assessment-insulin
resistance; IFG, impaired fasting glucose; LDL, low-density lipoprotein; MetS, metabolic syndrome; NFG, normal fasting glucose; SA,
sphinganine; SO, sphingosine; T2DM, type 2 diabetes mellitus.
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sphingoid bases in plasma but refer to the sphingoid base
composition of all plasma sphingolipids (independent
whether free or N-acylated).
Statistical analysis
Continuous variables were log-transformed and the
means were compared using the two-sided t test or ana-
lysis of variance followed by the Bonferroni correction.
Categorical variables were compared using the χ2 test.
Prospective analysis for the development of T2DM
was performed using binary logistic regression. Mean
comparisons were done between those individuals who
developed T2DM and those who did not. A two-sided t
test was performed on the log-transformed variables.
Univariate binary logistic regression models were calcu-
lated to evaluate the predictive role of each of the
measured variables. Multivariate logistic regression
models were then performed to adjust for the trad-
itional predictors. Since the number of cases in the
incident T2DM group is 32, we limited the number of
independent variables to two to avoid overﬁtting.
Log-transformed and normalized variables in SD units
were used for the logistic regression models. Statistical
analyses were performed in SPSS V.16.0 (IBM, Zurich,
Switzerland).
RESULTS
In a cross-sectional design, we ﬁrst compared the sphin-
goid base plasma proﬁles from patients with and without
MetS (table 1) as well as from participants with NFG,
IFG, and T2DM (table 2).
At baseline, plasma concentrations of 1-deoxySLs and
C20SA-based sphingolipids were signiﬁcantly higher in
patients with MetS (table 1; p=5.56×10−6 for 1-deoxySO,
p=3.26×10−5 for 1-deoxySA, and p=2.81×10−4 for C20SA).
Other sphingoid bases such as C16SO, C17SO, C18SAdiene,
C18SO, and C19SO were lower but did not reach statistical
signiﬁcance after correction for multiple comparisons.
Both 1-deoxySO and 1-deoxySA were elevated in
patients with T2DM (table 2) and in patients with IFG
but only 1-deoxySO remained signiﬁcantly elevated after
the Bonferroni correction for multiple comparisons
(p<4.1×10−4). It should be noted that Bonferroni cor-
rection is a very rather conservative correction method
that increases the likelihood of false negatives.
Therefore, the lack of signiﬁcance for 1-deoxySA in
patients with T2DM after correction cannot be necessar-
ily interpreted as no difference in 1-deoxySA levels. It is
rather likely that this is a false-negative ﬁnding as two
independent cohorts showed a signiﬁcant increase in
1-deoxySA and 1-deoxySO in patients with T2DM.18 23
Interestingly, C20SA was also found to be signiﬁcantly
elevated in patient with T2DM. Other sphingoid bases
were not signiﬁcantly different.
Correlation analysis (table 3) revealed a strong positive
correlation between 1-deoxySLs, TGs, glucose, HbA1c,
insulin, and homeostatic model assessment-insulin
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resistance while the serine-derived sphingolipids corre-
lated with low-density lipoprotein cholesterol and total
cholesterol.
The potential of plasma sphingoid bases as biomarkers
to predict the risk to develop T2DM was assessed by com-
paring baseline levels between individuals who developed
T2DM during the follow-up period of the study
(incident T2DM, n=32) and those who did not (no inci-
dent T2DM, n=70). Baseline 1-deoxySLs were signiﬁ-
cantly higher in the incident T2DM group (table 4) as
were HbA1c and TGs, (p=0.004 for 1-deoxySO, p=0.011
for 1-deoxySA, p=0.006 for HbA1c, and p=0.024 for TGs).
Univariate binary logistic regression (table 5) revealed
that 1-deoxySLs, along with typical risk factors such as
HbA1c, TGs, hypertension, and the presence of an
MetS, were signiﬁcant predictors for the development of
T2DM. Surprisingly also, serum potassium was a pre-
dictor for incident T2DM in the univariate analysis ,
which is in accordance with a recent report from the
Atherosclerosis Risk in Communities (ARIC) study.24
The predictive potential of the 1-deoxySLs was further
evaluated in a bivariate binary logistic regression model
by using each of the signiﬁcant variables from the uni-
variate models as covariates (table 5) as well as other
Table 4 Baseline values of clinical variables and sphingolipid levels in the incident T2DM group and the group which did not
develop T2DM until the end of the study period (8 years)
No iT2DM (n=70) iT2DM (n=32) p Value
Age (years) 61.3±9.1 64.8±10.7 0.130
Sex (female) 26 (37.14%) 11 (34.38%) 0.787
Hypertension (WHO) 28 (40%) 19 (59.38%) 0.069
History of smoking 37 (52.86%) 14 (43.75%) 0.393
Coronary artery stenosis >50% 38 (54.29%) 23 (71.88%) 0.093
MetS ATP III Definition 15 (21.43%) 14 (43.75%) 0.020
BMI 26.4±3.3 27±5.3 0.722
Waist circumference (cm) 92.5±10.5 96.6±13.8 0.162
Waist-to-hip ratio 0.9±0.1 1±0.1 0.150
Cholesterol (mmol/L) 5.6±1 5.8±1.3 0.670
LDL (mmol/L) 3.5±0.8 3.4±0.9 0.659
HDL (mmol/L) 1.3±0.4 1.3±0.4 0.900
Triglycerides (mmol/L) 1.6±0.9 2.2±1.6 0.024
Glucose (mmol/L) 5.8±1.1 5.8±0.9 0.793
HbA1c (%) 5.7±0.4 6±0.5 0.006
Insulin (µU/mL) 9±4.6 16±26.6 0.249
HOMA-IR 2.3±1.2 2.9±2.2 0.576
Systolic BP 131.6±19.1 140.5±21.1 0.041
Diastolic BP 76.5±11 79.8±14.1 0.295
CRP 0.7±1 0.8±1.5 0.773
Serum potassium 4.3±0.4 4.5±0.3 0.027
Creatinine (mg/dL) 1.1±0.1 1.2±1 0.194
GFR (Mayo) 89.5±15.3 85±23 0.111
Diuretics 20 (28.57%) 12 (37.5%) 0.367
Antihypertensive drugs 57 (81.43%) 31 (96.88%) 0.035
Lipid-lowering drugs 37 (52.86%) 16 (50%) 0.789
C16SO (µmol/L) 15.27±5.34 16.29±8.99 0.937
C16SA (µmol/L) 0.46±0.19 0.52±0.42 0.518
C17SO (µmol/L) 7.96±2.78 8.66±3.88 0.874
C18PhytoSO (µmol/L) 0.11±0.04 0.13±0.09 0.284
C18SAdiene (µmol/L) 28.37±7.55 30.76±12.14 0.566
C18SO (µmol/L) 93.08±19.41 101.83±32.38 0.188
C18SA (µmol/L) 3.28±1.12 3.66±2.17 0.518
C19SO (µmol/L) 2.8±1.14 3.07±1.48 0.470
C20SO (µmol/L) 0.17±0.05 0.19±0.08 0.187
C20SA (µmol/L) 0.02±0.01 0.03±0.02 0.613
1-deoxySO (µmol/L) 0.14±0.06 0.2±0.17 0.004
1-deoxySA (µmol/L) 0.07±0.03 0.09±0.08 0.011
p Values are calculated using the t test on the log transformed variables (variables in bold font are p<0.05).
ATP, Adult Treatment Panel; BMI, body mass index; CRP, C reaction protein; GFR (Mayo) Glomerular filtration rate (Mayo equation); Hb,
hemoglobin; HbA1c, glycated Hb; HDL, high-density lipoprotein; HOMA-IR, Homeostatic model assessment-insulin resistance; iT2DM,
incident type 2 diabetes mellitus; LDL, low-density lipoprotein; MetS, metabolic syndrome; SA, sphinganine; SO, sphingosine.
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risk factors (age, sex, BMI) and the use of lipid-lowering
drugs. Baseline 1-deoxySO remained signiﬁcant predic-
tors for the development of T2DM even after adjustment
for age, sex, BMI, HbA1c, MetS, systolic blood pressure,
serum potassium, or the use of lipid-lowering drugs
(table 5). Interestingly, adjusting for TGs made both
TGs and 1-deoxySO non-signiﬁcant predictors while the
regression model was still signiﬁcant, possibly due to the
Table 5 Binary logistic regression models results for incident T2DM showing the ORs for the univariate and multivariate models
OR (95% CI) p Value
Univariate binary logistic regression models
1-deoxySO 2.09 (1.22–3.58) 0.007
1-deoxySA 1.83 (1.12–2.99) 0.016
TG 1.69 (1.05–2.7) 0.030
HbA1c 4.11 (1.42–11.85) 0.009
Systolic BP 1.64 (1.01–2.65) 0.044
Potassium 1.78 (1.05–3.03) 0.03
MetS 2.85 (1.16–7.03) 0.023
Multivariate binary logistic regression models
Model 1 1-deoxySO 2.32 (1.31–4.12) 0.004
Age 1.63 (0.99–2.69) 0.054
Model 2 1-deoxySO 2.13 (1.23–3.7) 0.007
Sex 1.17 (0.46–2.96) 0.746
Model 3 1-deoxySO 2.05 (1.2–3.5) 0.008
BMI 1.09 (0.68–1.75) 0.731
Model 4 1-deoxySO 1.97 (1.13–3.43) 0.017
MetS 2.37 (0.93–6.06) 0.071
Model 5 1-deoxySO 2.1 (1.22–3.59) 0.007
Lipid-lowering drugs 0.85 (0.36–2.04) 0.720
Model 6 1-deoxySO 1.76 (0.94–3.27) 0.076
TG 1.31 (0.75–2.27) 0.344
Model 7 (stepwise logistic regression) 1-deoxySO 2.03 (1.19–3.49) 0.010
Zlog_TG 0.342
Model 8 1-deoxySO 2.1 (1.19–3.71) 0.010
HbA1c 4.11 (1.37–12.34) 0.012
Model 9 1-deoxySO 2.13 (1.22–3.72) 0.008
Systolic BP 1.73 (1.04–2.86) 0.033
Model 10 1-deoxySO 1.88 (1.03–3.42) 0.039
Potassium 1.62 (0.94–2.78) 0.083
Model 1 1-deoxySA 2.0 (1.19–3.36) 0.009
Age 1.6 (0.99–2.61) 0.057
Model 2 1-deoxySA 1.83 (1.12–3) 0.017
Sex 0.93 (0.37–2.29) 0.869
Model 3 1-deoxySA 1.82 (1.12–2.97) 0.016
BMI 1.13 (0.71–1.8) 0.607
Model 4 1-deoxySA 1.68 (1.01–2.79) 0.048
MetS 2.26 (0.88–5.79) 0.088
Model 5 1-deoxySA 1.83 (1.12–3) 0.016
Lipid-lowering drugs 0.88(0.37–2.09) 0.770
Model 6 1-deoxySA 1.56 (0.9–2.71) 0.112
TG 1.38 (0.81–2.36) 0.234
Model 7 (stepwise logistic regression) 1-deoxySA 1.81 (1.1–2.96) 0.019
TG – 0.230
Model 8 1-deoxySA 1.76 (1.06–2.92) 0.030
HbA1c 3.78 (1.29–11.13) 0.016
Model 9 1-deoxySA 1.76 (1.07–2.89) 0.025
Systolic BP 1.57 (0.96–2.56) 0.071
Model 10 1-deoxySA 1.62 (0.94–2.77) 0.082
Potassium 1.69 (0.99–2.9) 0.055
Variables are log transformed and standardized in SD units.
ORs are reported per increase of 1 SD unit. Variables in bold font are significant (p<0.05).
BMI, body mass index; BP, blood pressure; HbA1c, glycated Hb; MetS, metabolic syndrome; SA, sphinganine; SO, sphingosine; T2DM, type
2 diabetes mellitus; TG, triglycerides.
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high colinearity between TGs and 1-deoxySO. However,
using stepwise logistic regression, plasma 1-deoxySO
remained signiﬁcantly included in the regression model
while TGs became non-signiﬁcant (table 5). 1-DeoxySA
showed a similar independent predictive role with sig-
niﬁcant OR after adjusting for the same risk factors,
apart from serum potassium which again had a high
colinearity with 1-deoxySA.
CONCLUSIONS
In the current study, we showed that plasma 1-deoxySLs
are elevated in T2DM and are novel and independent
predictors of T2DM. In two previous cross-sectional
studies, we found that 1-deoxySLs are elevated in the
plasma of patients with MetS18 and T2DM.19 These pre-
vious ﬁndings were conﬁrmed in this study. In extension
of our previous ﬁndings, we also showed that 1-deoxySLs
are elevated in patients with IFG, suggesting that these
lipids are already elevated in an early phase of T2DM.
We also found that elevated 1-deoxySLs plasma levels are
signiﬁcantly and independently associated with an
increased risk of developing T2DM after adjusting for
several traditional risk factors and lipid-lowering drugs.
Pathologically elevated plasma 1-deoxySLs were origin-
ally found in the context of a rare inherited sensory
neuropathy (Hereditary sensory and autonomic neur-
opathy type I, HSAN1) which is associated with several
missense mutations in SPT.25–27 These mutations induce
a shift in the substrate speciﬁcity of the enzyme that
results in an increased 1-deoxySL formation.27 Further
studies showed that 1-deoxySLs are neurotoxic and accu-
mulate in the peripheral nerves but not in the brain or
other organs of transgenic HSAN1 animals.27 28
However, it is not fully understood why 1-deoxySLs are
also elevated in conditions of metabolic disorders such
as MetS or T2DM. Cell culture studies showed that the
increased availability of alanine alone is not sufﬁcient to
induce a signiﬁcant 1-deoxySL formation. In contrast,
cells which were either cultured at high density or which
were treated with the CerS inhibitor fumonisin B1 (FB1)
generate signiﬁcant amounts of 1-deoxySLs.17 This sug-
gests that a yet unknown regulatory mechanism is under-
lying the formation of these lipids in metabolic diseases.
Elevated 1-deoxySL levels were also found in plasma of
high fat and high fructose fed prediabetic and diabetic
monkeys.29 This corroborates our observation that 1-
deoxySLs are already elevated early in the course of
T2DM development. Since 1-deoxySLs are cytotoxic, it is
conceivable that they could play a role in the pathogen-
esis of T2DM such as β-cell failure and other
T2DM-related sequelae, like retinopathy or diabetic
neuropathy. Indeed, the addition of 1-deoxySA is toxic
to β cells in culture and results in cytoskeletal aberra-
tions and cell death.30 These effects were at least partly
mediated though JNK and p38 MAPK pathways. In the
same work, we showed that 1-deoxySA compromises
glucose-stimulated insulin secretion from primary β cells
in vitro. These ﬁndings further support the notion that
1-deoxySLs are not only early biomarkers in the course
of T2DM development but might also be involved in the
pathogenesis of T2DM. Given their reported neurotoxic
activity in HSAN1, it is also feasible that 1-deoxySLs play
a role in the pathogenesis of the diabetic neuropathy.
Recently, we showed that lowering plasma 1-deoxySL
with L-serine was associated with a signiﬁcant improve-
ment in the neuropathy in a diabetic rat model.31 This
indicates that 1-deoxySLs act as both predictive biomar-
kers and potential therapeutic targets in T2DM.
We also found that plasma C20SA levels are increased in
patients with IFG and T2DM. The origin and mechan-
isms by which plasma C20SA is formed are not fully clear
yet. It has been shown that stearoyl coenzyme A is used by
SPT as a substrate to form C20 sphingoid bases.
32 The
mechanism that regulates such a substrate shift is not
clearly elucidated but several factors could play a role.
The small SPT subunits (ssSPTa/b)8 which interact with
SPT can modulate the afﬁnity of SPT for various acyl
coenzyme A substrates. Moreover, we have shown that the
SPTLC3 subunit inﬂuences the afﬁnity of SPT for various
acyl coenzyme As.10 33 Whether these proteins play a role
in the pathogenesis of T2DM or whether plasma C20SA
levels are associated with other pathological processes
related to T2DM is currently not clear.
The availability of 8-year follow-up data including bian-
nual oral glucose tolerance tests is a substantial strength of
this study. However, the total number of patients who
developed incident T2DM during the follow-up period
was limited and did not allow us to adjust for all possible
confounders without the risk of over-ﬁtting. At that point,
we cannot fully exclude a possible inﬂuence of other con-
founders than HbA1c and MetS which were adjusted for.
Furthermore, the investigated individuals were hospita-
lized with chest pain and underwent coronary angiog-
raphy for the evaluation of established or suspected CAD.
Our study cohort may therefore be at a higher risk to
develop T2DM than the general population. Despite these
limitations, the study showed that 1-deoxySO and
1-deoxySA levels are signiﬁcant, independent, and predict-
ive risk markers and comparable to other established risk
factors like HbA1c and MetS.
However, larger and optimally interventional studies
are needed to further conﬁrm the clinical relevance of
1-deoxySLs as prognostic biomarkers and to explore
their potential in the risk management of patients with
MetS and T2DM.
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